EnWave Announces Radiant Energy Vacuum Technology Testing Agreement With Tier 1 Pharmaceutical Company for Monoclonal

EnWave Announces Radiant Energy Vacuum Technology Testing Agreement With Tier 1 
Pharmaceutical Company  for Monoclonal Antibodies 
NEWS RELEASE TRANSMITTED BY Marketwired 
FOR: EnWave Corporation 
TSX VENTURE SYMBOL:  ENW
FRANKFURT SYMBOL:  E4U 
MARCH 10, 2014 
EnWave Announces Radiant Energy Vacuum Technology Testing Agreement With Tier 1
Pharmaceutical Company  for Monoclonal Antibodies 
VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 10, 2014) - EnWave
Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave", or the
"Company") announced today that it has signed a Testing Agreement
(the "Agreement") with a Tier 1 pharmaceutical company (the
"Tier 1") that is in the top five globally for Research and
Development spending. The Agreement allows the Tier 1 to exclusively test
EnWave's Radiant Energy Vacuum ("REV(TM)") technology for the
dehydration of monoclonal antibodies ("mAbs"). The testing period is
expected to begin in late March 2014.  
Prior to signing this Agreement, EnWave received positive results in 2011 from
a 12 month study comparing the Company's REV(R) dehydration technology
against the standard industrial drying method, freeze drying, in the
dehydration of pure samples of a FITC-conjugated and unconjugated
animal-derived mAbs. The results showed that the drying methods were equivalent
in terms of the structural changes incurred by the antibodies both immediately
post-dehydration, and over the course of the 12 month shelf-life period, but
that the samples dried using REV(R) were dehydrated in considerably less time
than required for freeze drying. This was a significant test result as mAbs are
much more sensitive and therefore prone to degradation during dehydration. 
mAbs are produced by a single clone of cells grown in culture, that is both
pure and specific and is capable of proliferating indefinitely to produce
unlimited quantities of identical antibodies. Beyond basic research, in recent
years, therapeutic mAbs have become an increasingly important component of
pharmacotherapy and have made a significant impact on the drug discovery and
development process.  
Although antibodies are not considered live organisms, dehydration can cause
them to become inactive, and therefore ineffective for use in pharmaceutical
and other products, by changing or "denaturing" their outer protein
structure. 
"We have proven that REV(TM) technology can efficiently dehydrate
monoclonal antibodies while preserving their efficacy," stated Dr. Tim
Durance, Chairman & Co-CEO of EnWave Corporation. "This Agreement will
provide the opportunity to exhibit the value proposition to this leading Tier 1
pharmaceutical partner." 
About EnWave  
EnWave Corporation is a Vancouver-based industrial technology company
developing commercial applications for its proprietary Radiant Energy Vacuum
(REV(TM)) dehydration technology. EnWave aims to sign royalty-bearing
commercial licenses with leading food and pharmaceutical companies for the use
of its revolutionary technology. Thus far the Company has signed commercial
licenses with Bonduelle, a global leader in the production of vegetables, for
the processing of dehydrofrozen vegetables; Hormel Foods Corporation, a major
processed meat manufacturer, for the production of healthy dried meat products;
Milne Fruit Product, EnWave's first major licensee, for the production of
several dehydrated fruit and vegetable products in the whole, fragmented and
powdered form; a leading North American enzyme company, to dehydrate a series
of food-related enzymes for their Tier 1 clients; and Napa Mountain Spice
Company, to dry high-quality California bay leaves. In addition to these
licenses, EnWave has formed a Limited Liability Partnership with Lucid Capital
Management to develop, manufacture, market and sell all-natural cheese snack
products in the United States under the Moon Cheese(R) brand.  
Also, EnWave has entered into a wide range of research and collaboration
agreements with an expanding list of multinational companies, including Nestle,
Kellogg's, Grupo Bimbo, Grimmway Farms, Ocean Spray Cranberries, Cherry
Central, Sun-Maid Growers, Gay Lea Foods, R.J. Reynolds and Merck. EnWave is
introducing REV(TM) as a new dehydration standard in the food and biological
material sectors: potentially faster and cheaper than freeze drying, with
better end product quality than air drying or spray drying. 
EnWave currently has six REV(TM) platforms: commercial-scale nutraREV(R) and
MIVAP(R) are used in the food industry to dry fruits, vegetables, meat, herbs
and seafood quickly and at low-cost, while maintaining high levels of
nutrition, taste, texture and colour. The Company is also developing
powderREV(R) for bulk dehydration of food cultures, probiotics and fine
biochemicals such as enzymes; quantaREV(TM) for continuous, high-volume
low-temperature drying of pastes, gels, liquids, or particulates; and
bioREV(TM) and freezeREV(TM) as new methods to stabilize and dehydrate
biopharmaceuticals such as vaccines and antibodies. More information about
EnWave is available at www.enwave.net.  
EnWave Corporation 
Dr. Tim Durance, Chairman & Co-CEO  
Safe Harbour for Forward-Looking Information Statements: This press release may
contain forward-looking information based on management's expectations,
estimates and projections. All statements that address expectations or
projections about the future, including statements about the Company's
strategy for growth, product development, market position, expected
expenditures, and the expected synergies following the closing are
forward-looking statements. All third party references to market information in
this release are not guaranteed to be accurate as the Company did not conduct
the original primary research. These statements are not a guarantee of future
performance and involve a number of risks, uncertainties and assumptions.
Although the Company has attempted to identify important factors that could
cause actual results to differ materially, there may be other factors that
cause results not to be as anticipated, estimated or intended. There can be no
assurance that such statements will prove to be accurate, as actual results and
future events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements. 
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 
-30-
FOR FURTHER INFORMATION PLEASE CONTACT: 
EnWave Corporation
Mr. John McNicol
President & Co-CEO
(604) 601-8524
john.mcnicol@enwave.net
or
EnWave Corporation
Mr. Brent Charleton
Vice President, Corporate Affairs
(778) 378-9616
bcharleton@enwave.net 
INDUSTRY:  Medical and Healthcare - Alternative, Medical and Healthcare -
Dentistry, Medical and Healthcare - Mental Health, Medical and Healthcare -
Nursing, Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
Drugs 
SUBJECT:  BFC 
-0-
-0- Mar/10/2014 13:30 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.